Preclinical models for cell cycle-targeted therapies.
Deregulation of the cell cycle machinery is frequently associated to tumor development in most cell types. Many of these tumor-associated alterations result in the abnormal activation of cyclin-dependent protein kinases (Cdks) involved in the G1/S transition. Recent results from the genetic analysis of cyclins and Cdks in mouse models have raised some questions regarding the relevance of these molecules in cell cycle-targeted strategies for cancer therapy. The comprehensive evaluation of these biochemical and genetic data seems to be a necessary given the relevance of these and other new cell cycle kinases as targets for therapeutic approaches in cancer.